HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...
Cipla share price declined 2 percent after the United States Food and Drug Administration (USFDA) has classified the inspection as Voluntary Action Indicated (VAI). At 09:29am, Cipla was quoting ...
After topping the Street's expectations with its Q3 earnings, Cipla announced plans to launch two key drugs in FY26—the respiratory drug Advair and the oncology drug Abraxane. Umang Vohra ...
HYDERABAD/BENGALURU (Reuters) -Cipla, one of India's largest drugmakers by sales, reported a bigger-than-expected third-quarter profit on Tuesday helped by strong domestic demand, and said the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback